- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Monopar Therapeutics, having taken over sponsorship of ALXN1840 from Alexion, is enrolling in clinical trials and must comply with federal regulations.
5 reports, 2 independent
Updated Aug 19
Gone quiet
- Reports
- 5
- Developments
- 6
- Repetition
- 20%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Monopar Therapeutics, having taken over sponsorship of ALXN1840 from Alexion, is enrolling in clinical trials and must comply with federal regulations.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Monopar is preparing for FDA approval, drawing on experience from Horizon Therapeutics.1 source
- Monopar Therapeutics submitted a New Drug Application (NDA) to the FDA for review.Sub-event
Monopar Therapeutics initiated rolling NDA submission for ALXN1840.1 source
- The FDA granted Rare Pediatric Disease designation to Monopar Therapeutics.Sub-event
Monopar took over sponsorship of ALXN1840 from Alexion and is moving forward with clinical trials.1 source
- MNPR received FDA EAP authorization for ALXN1840 treatment of Wilson disease.
Keep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
-
Monopar Therapeutics
biopharmaceutical company
Nothing else this week.
- FDA
Related events
Coverage
Newest first; wire copies grouped- finanznachrichten.de
- finanznachrichten.de
- GlobeNewswireMonopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments WILMETTE, Ill., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Na
- Unknown outlet
- Unknown outlet